Skip to main content
Featured News

Development of a new Gadolinium-based Contrast Agent

The finding several years ago that small amounts of gadolinium (Gd) could be deposited in the brains of patients who had received several doses of certain gadolinium-based contrast agents (GBCAs), (albeit without any apparent clinical consequences) prompted the European regulatory authorities to withdraw some GBCAs


Read more here :New Gadolinium Contrast Agent Guerbet Bourrinet June 2022